Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination (Q36537615)

14 August 2017

1 reference

title

Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination (English)

1 reference

14 August 2017

cervix uterine cancer

1 reference

3

Allan Hildesheim

0 references

Silvia de Sanjosé

series ordinal

4

object named as

Silvia de Sanjosé

0 references

Eduardo L. Franco

object named as

Eduardo L Franco

series ordinal

1

0 references

Jack Cuzick

series ordinal

2

object named as

Jack Cuzick

1 reference

PubMed ID

16844268

14 August 2017

language of work or name

English

0 references

publication date

8 June 2006

1 reference

14 August 2017

1 reference

14 August 2017

24 Suppl 3

1 reference

14 August 2017

S3/171-7

1 reference

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

14 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.061

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.061

Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.061

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.061

Potential health and economic impact of adding a human papillomavirus vaccine to screening programs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.061

Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.061

Evaluating human papillomavirus vaccination programs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.061

Cervical screening in the National Breast and Cervical Cancer Early Detection Program, 1995-2001

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.061

Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.061

Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.061

Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.061

The carcinogenicity of human papillomavirus types reflects viral evolution.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.061

Improving adolescent health: focus on HPV vaccine acceptance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.061

Understanding and overcoming barriers to human papillomavirus vaccine acceptance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.061

Attitudes about human papillomavirus vaccine among family physicians.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.061

Overview of the European and North American studies on HPV testing in primary cervical cancer screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.061

Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.061

Management of women who test positive for high-risk types of human papillomavirus: the HART study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.061

10.1016/J.VACCINE.2006.05.061

7 January 2021

Identifiers

DOI

1 reference

14 August 2017

1 reference

PubMed ID

16844268